scholarly journals The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

Public Health ◽  
2021 ◽  
Vol 198 ◽  
pp. 230-237
Author(s):  
Katarzyna Jabłońska ◽  
Samuel Aballéa ◽  
Mondher Toumi
Keyword(s):  
Real Life ◽  
The Real ◽  
Life Impact

scholarly journals How Relevant Is It to Use Mineral Proxies to Mimic the Atmospheric Reactivity of Natural Dust Samples? A Reactivity Study Using SO2 as Probe Molecule

Minerals ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 282
Author(s):  
Darya Urupina ◽  
Manolis N. Romanias ◽  
Frederic Thevenet
Keyword(s):  
High Performance ◽  
Real Life ◽  
Complex Mixtures ◽  
Experimental Conditions ◽  
The Real ◽  
Atmospheric Processes ◽  
Real Effects ◽  
Mineral Aerosols ◽  
Life Impact ◽  
Reactivity Study

The experimental investigation of heterogeneous atmospheric processes involving mineral aerosols is extensively performed in the literature using proxy materials. In this work we questioned the validity of using proxies such as Fe2O3, FeOOH, Al2O3, MgO, CaO, TiO2, MnO2, SiO2, and CaCO3 to represent the behavior of complex mixtures of minerals, such as natural desert and volcanic dusts. Five volcanic dusts and three desert dusts were compared to a number of metal oxides, commonly used in the literature to mimic the behavior of desert dusts in the ability to form sulfites and sulfates on the surface exposed to SO2 gas. First, all samples were aged at room temperature, atmospheric pressure, under controlled experimental conditions of 175 ppm SO2 for 1 h under 30% of relative humidity. Second, they were extracted with 1% formalin and analyzed by High-Performance Liquid Chromatography (HPLC) to quantify and compare the amount of sulfites and sulfates formed on their surfaces. It was evidenced that under the experimental conditions of this study neither one selected pure oxide nor a mixture of oxides can adequately typify the behavior of complex mixtures of natural minerals. Therefore, to evaluate the real-life impact of natural dust on atmospheric processes it is of vital importance to work directly with the natural samples, both to observe the real effects of desert and volcanic dusts and to evaluate the relevancy of proposed proxies.

scholarly journals Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia

2015 ◽  
Vol 6 (3) ◽  
pp. 389-393 ◽  
Author(s):  
Simon Heller ◽  
Natalie Houwing ◽  
Nana Kragh ◽  
Uffe Jon Ploug ◽  
Annie Nikolajsen ◽  
...  
Keyword(s):  
Real Life ◽  
The Real ◽  
Acute Hyperglycaemia ◽  
Life Impact

scholarly journals Patterns of COVID-19 pandemic dynamics following deployment of a broad national immunization program

2021 ◽  
Author(s):  
Hagai Rossman ◽  
Smadar Shilo ◽  
Tomer Meir ◽  
Malka Gorfine ◽  
Uri Shalit ◽  
...  
Keyword(s):  
Temporal Dynamics ◽  
Vaccination Campaign ◽  
Descriptive Analysis ◽  
Age Groups ◽  
Real Life ◽  
Population Level ◽  
Older Individuals ◽  
The Real ◽  
Younger Age ◽  
Life Impact

AbstractStudies on the real-life impact of the BNT162b2 vaccine, recently authorized for the prevention of coronavirus disease 2019 (COVID-19), are urgently needed. Here, we analysed the temporal dynamics of the number of new COVID-19 cases and hospitalization in Israel following a rapid vaccination campaign initiated on December 20th, 2020. We conducted a retrospective descriptive analysis of data originating from the Israeli Ministry of Health (MOH) from March 2020 to February 2021. In order to distill the possible effect of the vaccinations from other factors, including a third lockdown imposed in Israel on January 2021, we compared the time-dependent changes in number of COVID-19 cases and hospitalizations between (1) individuals aged 60 years and older, eligible to receive the vaccine earlier, and younger age groups; (2) the latest lockdown (which was imposed in parallel to the vaccine rollout) versus the previous lockdown, imposed on September 2020; (3) early-vaccinated cities compared to late-vaccinated cities; and (4) early-vaccinated geographical statistical areas (GSAs) compared to late-vaccinated GSAs. In mid-January, the number of COVID-19 cases and hospitalization started to decline, with a larger and earlier decrease among older individuals, followed by younger age groups, by the order in which they were prioritized for vaccination. This fast and early decline in older individuals was more evident in early-vaccinated compared to late-vaccinated cities. Such a pattern was not observed in the previous lockdown. Our analysis demonstrates evidence for the real-life impact of a national vaccination campaign in Israel on the pandemic dynamics. We believe that our findings have major public health implications in the struggle against the COVID-19 pandemic, including the public ’s perception of the need for and benefit of nationwide vaccination campaigns. More studies aimed at assessing the effectiveness and impact of vaccination both on the individual and on the population level, with longer followup, are needed.

scholarly journals The real-life impact of vaccination on COVID-19 mortality in Europe and Israel

2021 ◽  
Author(s):  
Katarzyna Jablonska ◽  
Samuel Aballea ◽  
Mondher Toumi
Keyword(s):  
Regression Models ◽  
Real Life ◽  
The Real ◽  
Public Data ◽  
Life Impact ◽  
Mixed Regression ◽  
Adjustment Factors ◽  
Indirect Protection ◽  
Mobility Reduction

OBJECTIVES: This study aimed at estimating the real-life impact of vaccination on COVID-19 mortality, with adjustment for SARS-CoV-2 variants spread and other factors across Europe and Israel. METHODS: Time series analysis of daily number of COVID-19 deaths was performed using non-linear Poisson mixed regression models. Variants' frequency, demographic, climate, health and mobility characteristics of thirty-two countries were considered as potentially relevant adjustment factors between January 2020 and April 2021. RESULTS: The analysis revealed that vaccination efficacy in terms of protection against deaths was equal to 72%, with a lower reduction of number of deaths for B.1.1.7 versus non-B.1.1.7 variants (70% and 78%, respectively). Other factors significantly related to mortality were arrivals at airports, mobility change from the pre-pandemic level and temperature. CONCLUSIONS: Our study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, although lower than expected from clinical trials. This suggests the absence of indirect protection for non-vaccinated individuals. Results also show that vaccination effectiveness against mortality associated with the B.1.1.7 variant is slightly lower compared with other variants. Lastly, this analysis confirms the role of mobility reduction, within and between countries, as an effective way to reduce COVID-19 mortality and suggests the possibility of seasonal variations in COVID-19 incidence.

The "real life" impact of adding bevacizumab to first-line treatment of metastatic colorectal cancer: A retrospective large database study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e14571-e14571
Author(s):  
Ariel Hammerman ◽  
Sari Greenberg-Dotan ◽  
Erez Battat ◽  
Haim Bitterman ◽  
Baruch Brenner
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Combination Chemotherapy ◽  
Real Life ◽  
Progression Free Survival ◽  
Line Treatment ◽  
Database Study ◽  
The Real ◽  
Life Impact ◽  
Retrospective Database

e14571 Background: Bevacizumab is included in the Israeli National List of Reimbursed Drugs (NLRD) for 1st line treatment of all metastatic colorectal cancer (mCRC) patients since 7/2006. This study evaluates the "real life" impact of adding bevacizumab to 1st line treatment of mCRC by comparing patients' outcomes before and after the drug's availability in the NLRD. Methods: We conducted a retrospective database study ,using the computerized databases of Clalit Health Services' (CHS), Israel's largest health care provider, to compare two cohorts: (A) all CHS' patients diagnosed with mCRC between 1/2000-12/2004 that received 1st line irinotecan or oxaliplatin-based combination chemotherapy (before bevacizumab was introduced), and (B) all CHS's patients that started 1st line treatment with irinotecan or oxaliplatin-based combination chemotherapy and bevacizumab between 7/2006 and 8/2009 (allowing a minimum follow-up of 3 years). The primary endpoint was overall survival (OS) and the secondary endpoints were 1st line progression free survival (PFS) and metastatectomy rates. Since data on actual progression status was unavailable, PFS was defined as the duration of 1st line treatment. As CHS covers more than 50% of the Israeli population, our study may represent the general care received by Israeli patients with mCRC. Results: The study population included 1,739 patients: 1,052 in cohort A and 687 in cohort B. Patient demographics were similar between the cohorts. Median OS was 15.0 months for cohort A (95% CI: 13.4–16.6) and 23.0 months for cohort B (95% CI: 21.7–24.3), with an unadjusted hazard ratio (HR) of 0.71 (95% CI: 0.64-0.80, p<0.0001). Median PFS was 9.8 months (95% CI: 9.0–10.5) for cohort A and 14.0 months (95% CI: 13.0-15.0) for cohort B, with a HR of 0.80 (95% CI: 0.71-0.87, p<0.0001). The rate of metastatectomies was significantly higher in cohort B (8.1% vs. 3.9%; P = 0.001). Conclusions: In this retrospective database analysis, OS, PFS and metastatectomy rates of 1st line treatment of mCRC were significantly higher in the later period of the study. The addition of bevacizumab to standard treatment of mCRC may have had a major contribution to this improvement.

scholarly journals A two-year evaluation of the ‘real life’ impact of COPD on patients in Germany: The DACCORD observational study

2017 ◽  
Vol 124 ◽  
pp. 57-64 ◽  
Author(s):  
Peter Kardos ◽  
Claus Vogelmeier ◽  
Heinrich Worth ◽  
Roland Buhl ◽  
Nadine S. Lossi ◽  
...  
Keyword(s):  
Observational Study ◽  
Real Life ◽  
The Real ◽  
Life Impact

scholarly journals P350 SAFIIR: Study of Anemia Following Intravenous Iron Repletion

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S371-S372
Author(s):  
L C Rioux ◽  
E J Bernard ◽  
M Bourgault ◽  
P Mondragon ◽  
V Rioux
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Transferrin Saturation ◽  
Real Life ◽  
Intravenous Iron ◽  
Deficiency Anemia ◽  
The Real ◽  
Iron Treatment ◽  
Life Impact ◽  
Iv Iron

Abstract Background The main objective of this study was to assess the prevalence of anemia and the secondary objectives aimed to evaluate the real-life impact of intravenous iron therapy on anemia correction in patients living with Inflammatory Bowel Disease (IBD). Methods We performed a retrospective cohort study of adult patients (18 to 80 years old) with a Crohn’s Disease or Ulcerative Colitis diagnosis who were followed at our clinic between January 2018 and March 2020. Clinical data were obtained from the patients’ electronic medical records. Iron-deficiency anemia was defined as hemoglobin (Hb) &lt; 12,0 g/dL and/or transferrin saturation (TSAT)&lt; 20 % and/or low serum iron (≤ 10 μmol/L). Intravenous (IV) iron treatment was defined as at least one infusion of iron isomaltoside, iron sucrose, or sodium ferric gluconate. The secondary analyses were performed in terms of IV iron treatments. Results Of the cohort of 556 IBD patients, 223 (40.1%) had an anemia diagnosis. Among the latter, 39 patients received an intravenous iron treatment and had laboratory results in the 8 weeks preceding and in the 8 weeks following the treatment. Table 1 shows the response to intravenous iron treatment in patients with baseline Hb &lt; 12,0 g/dL (n=28 patients, 47 IV iron infusions). Table 2 shows the changes in anemia-related laboratory values in the 8 weeks preceding and in the 8 weeks following intravenous iron treatment. Conclusion This was the first study to evaluate the prevalence of iron-deficiency anemia and the real-life impact of intravenous iron treatment among patients living with IBD in Quebec, Canada. The findings will serve as a baseline for subsequent interventions to improve the wellbeing and the quality of life of IBD patients with anemia.

Sign in / Sign up

Export Citation Format

Share Document